Cited by 1,308Cancer-related Molecular PathwaysChromatin Remodeling and CancerPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 57 of the 64 references it cites were found in a registry or an index.

Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome

Open access

Olive, Kenneth P., Tuveson, David A., Ruhe, Zachary C., Yin, Bob, Willis, Nicholas A., Bronson, Roderick T., Crowley, Denise, Jacks, Tyler·2004·Cell

DOI 10.1016/j.cell.2004.11.004

Open this paper in CoChat — free account Open PDF

Abstract

The p53 tumor suppressor gene is commonly altered in human tumors, predominantly through missense mutations that result in accumulation of mutant p53 protein. These mutations may confer dominant-negative or gain-of-function properties to p53. To ascertain the physiological effects of p53 point mutation, the structural mutant p53R172H and the contact mutant p53R270H (codons 175 and 273 in humans) were engineered into the endogenous p53 locus in mice. p53R270H/+ and p53R172H/+ mice are models of Li-Fraumeni Syndrome; they developed allele-specific tumor spectra distinct from p53+/- mice. In addition, p53R270H/- and p53R172H/- mice developed novel tumors compared to p53-/- mice, including a variety of carcinomas and more frequent endothelial tumors. Dominant effects that varied by allele and function were observed in primary cells derived from p53R270H/+ and p53R172H/+ mice. These results demonstrate that point mutant p53 alleles expressed under physiological control have enhanced oncogenic potential beyond the simple loss of p53 function.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2004.11.004

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
QUANTITATIVE STUDIES OF THE GROWTH OF MOUSE EMBRYO CELLS IN CULTURE AND THEIR DEVELOPMENT INTO ESTABLISHED LINES
Todaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,747
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
p63, a p53 Homolog at 3q27–29, Encodes Multiple Products with Transactivating, Death-Inducing, and Dominant-Negative Activities
Yang, A., Kaghad, M., Wang, Y., Gillett, E. S., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,118
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987

Flagged first, then by citations

Show all 64 references

7 of the 64 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Hinds, 1990, Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells, Cell Growth Differ, 1, 571
Kleihues, 1997, Tumors associated with p53 germline mutations, Am. J. Pathol, 150, 1

Sorted by citations

Items 501–600 of 1,000

p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy
Oh, H. J., Bae, J. M., Wen, X., Jung, S., Kim, Y.-H., Kim, K. J., Cho, N., Kim, J. H., Han, S., Kim, T., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0429-2 · Cited by 45
Cep55 overexpression promotes genomic instability and tumorigenesis in mice
Sinha, D., Nag, P., Nanayakkara, D. M., Duijf, P. H. G., Burgess, A., Raninga, P. V., Smits, V. A. J., Bain, A. L., Subramanian, G. N., Wall, M., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01304-6 · Cited by 48
miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis
Ge, W., Goga, A., He, Y., Silva, P. N., Hirt, C., Herrmanns, K., Guccini, I., Godbersen, S., Schwank, G., & Stoffel, M. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.09.029 · Cited by 48
Driver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progression
Bailey, P. J., Ridgway, R. A., Cammareri, P., Treanor-Taylor, M., Bailey, U., Schoenherr, C., Bone, M., Schreyer, D., Purdie, K. J., Thomson, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40822-9 · Cited by 47
Mutant p53 Promotes Tumor Cell Malignancy by Both Positive and Negative Regulation of the Transforming Growth Factor β (TGF-β) Pathway
Ji, L., Xu, J., Liu, J., Amjad, A., Zhang, K., Liu, Q., Zhou, L., Xiao, J., & Li, X. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.639351 · Cited by 47
Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment
Wong, G. S., Lee, J., Park, Y.-Y., Klein–Szanto, A. J., Waldron, T. J., Cukierman, E., Herlyn, M., Gimotty, P. A., Nakagawa, H., & Rustgi, A. K. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.17 · Cited by 48
ID4: a new player in the cancer arena
Dell’Orso, S., Ganci, F., Strano, S., Blandino, G., & Fontemaggi, G. (2010) · Oncotarget · doi:10.18632/oncotarget.108 · Cited by 46
ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function
Bado, I., Nikolos, F., Rajapaksa, G. K., Gustafsson, J.-Α., & Thomas, C. G. (2016) · Oncotarget · doi:10.18632/oncotarget.7300 · Cited by 47
A Quantitative Volumetric Micro-Computed Tomography Method to Analyze Lung Tumors in Genetically Engineered Mouse Models
Haines, B. B., Bettano, K. A., Chénard, M., Sevilla, R. S., Ware, C. M., Angagaw, M. H., Winkelmann, C. T., Tong, C., Reilly, J. F., Sur, C., et al. (2009) · Neoplasia · doi:10.1593/neo.81030 · Cited by 47
p53 and the regulation of hepatocyte apoptosis: implications for disease pathogenesis
Amaral, J. D., Castro, R. E., Steer, C. J., & Rodrigues, C. M. P. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.09.005 · Cited by 46
Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor developmentPreprint
Aubrey, B. J., Janic, A., Chen, Y., Chang, C. W. T., Lieschke, E., Diepstraten, S. T., Kueh, A. J., Bernardini, J. P., Dewson, G., O’Reilly, L. A., et al. (2018) · Genes & Development · doi:10.1101/gad.314286.118 · Cited by 50
Carrier-free nanoprodrug for p53-mutated tumor therapy via concurrent delivery of zinc-manganese dual ions and ROS
Wang, J., Qu, C. F., Shao, X., Song, G., Sun, J., Shi, D., Jia, R., An, H., & Wang, H. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.06.005 · Cited by 46
TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited
Shin, D.-Y. (2023) · Cancers · doi:10.3390/cancers15194816 · Cited by 46
Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor
Dorr, C. R., Janik, C. L., Weg, M. T., Been, R. A., Bader, J. M., Kang, R. J. D., Ng, B., Foran, L. A., Landman, S. R., O’Sullivan, M. G., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0674-t · Cited by 46
Genetic modeling of Li-Fraumeni syndrome in zebrafish
Parant, J. M., George, S. A., Holden, J. A., & Yost, H. J. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.003749 · Cited by 46
Relationship of p53 Overexpression on Cancers and Recognition by Anti-p53 T Cell Receptor-Transduced T Cells
Theoret, M. R., Cohen, C. J., Nahvi, A. V., Ngo, L. T., Suri, K. B., Powell, D. J., Dudley, M. E., Morgan, R. A., & Rosenberg, S. A. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.083 · Cited by 46
Dominant-Negative but not Gain-of-Function Effects of a p53.R270H Mutation in Mouse Epithelium Tissue after DNA Damage
Wijnhoven, S., Speksnijder, E. N., Liu, X., Zwart, E., vanOostrom, C. T. M., Beems, R. B., Hoogervorst, E. M., Schaap, M. M., Attardi, L. D., Jacks, T., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4681 · Cited by 46
A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas
Parameswaran, N., Bartel, C. A., Hernandez-Sanchez, W. M., Miskimen, K. L. S., Smigiel, J. M., Khalil, A. M., & Jackson, M. W. (2019) · Scientific Reports · doi:10.1038/s41598-019-49475-5 · Cited by 45
Induction of Ovarian Leiomyosarcomas in Mice by Conditional Inactivation of Brca1 and p53
Quinn, B. A., Brake, T., Xiang, H., Baxter-Jones, K., Litwin, S., Ellenson, L. H., & Connolly, D. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008404 · Cited by 46
Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target
Reinheckel, T., Peters, C., Krüger, A., Turk, B., & Vasiljeva, O. S. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00133 · Cited by 45
PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma
Ghannam-Shahbari, D., Jacob, E., Kakun, R. R., Wasserman, T., Korsensky, L., Sternfeld, O., Kagan, J., Bublik, D. R., Aviel‐Ronen, S., Levanon, K., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0040-z · Cited by 45
Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression
Valenti, F., Ganci, F., Fontemaggi, G., Sacconi, A., Strano, S., Blandino, G., & Agostino, S. D. (2015) · Oncotarget · doi:10.18632/oncotarget.2587 · Cited by 45
TP53 Mutants in the Tower of Babel of Cancer Progression
Bisio, A., Ciribilli, Y., Fronza, G., Inga, A., & Monti, P. (2014) · Human Mutation · doi:10.1002/humu.22514 · Cited by 44
MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice
Grabow, S., Delbridge, A. R. D., Valente, L. J., & Strasser, A. (2014) · Blood · doi:10.1182/blood-2014-09-601567 · Cited by 44
Analyzing tumor heterogeneity and driver genes in single myeloid leukemia cells with SBCapSeq
Mann, K. M., Newberg, J. Y., Black, M. A., Jones, D. J., Amaya‐Manzanares, F., Guzman‐Rojas, L., Kodama, T., Ward, J. M., Rust, A. G., van der Weyden, L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3637 · Cited by 42
Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication
Singh, S., Vaughan, C. A., Frum, R. A., Grossman, S. R., Deb, S., & Deb, S. P. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87724 · Cited by 45
Magnetic resonance imaging of cancer metabolism with hyperpolarized 13C-labeled cell metabolites
Hesketh, R. L., & Brindle, K. M. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.03.004 · Cited by 44
Peptide Aptamers Targeting Mutant p53 Induce Apoptosis in Tumor Cells
Guida, E., Bisso, A., Fenollar‐Ferrer, C., Napoli, M., Anselmi, C., Girardini, J. E., Carloni, P., & Sal, G. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0137 · Cited by 49
KDM6A regulates cell plasticity and pancreatic cancer progression by noncanonical activin pathway
Yi, Z., Wei, S., Jin, L., Jeyarajan, S., Yang, J., Gu, Y., Kim, H. S., Schechter, S., Lu, S., Paulsen, M. T., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.09.014 · Cited by 41
Breathing new insights into the role of mutant p53 in lung cancer
Chen, T., Ashwood, L. M., Kondrashova, O., Strasser, A., Kelly, G. L., & Sutherland, K. D. (2024) · Oncogene · doi:10.1038/s41388-024-03219-6 · Cited by 49
Detection of Precursor Lesions of Pancreatic Adenocarcinoma in PET-CT in a Genetically Engineered Mouse Model of Pancreatic Cancer
Fendrich, V., Schneider, R. A., Maitra, A., Jacobsen, I. D., Opfermann, T., & Bartsch, D. K. (2011) · Neoplasia · doi:10.1593/neo.10956 · Cited by 43
Transgenic and Knockout Mice Models to Reveal the Functions of Tumor Suppressor Genes
Taneja, P., Zhu, S., Maglic, D., Fry, E. A., Kendig, R. D., & Inoue, K. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7516 · Cited by 44
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance
Chen, L., & Tweddle, D. A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00173 · Cited by 43
Omics and therapy – A basis for precision medicine
Garay, J. P., & Gray, J. W. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.009 · Cited by 42
p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines
Ye, S., Shen, J. K., Choy, E., Cao, Y., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2944-z · Cited by 43
Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
Qiu, W., Polotskaia, A., Xiao, G., Di, L., Zhao, Y., Hu, W., Philip, J., Hendrickson, R. C., & Bargonetti, J. (2017) · npj Breast Cancer · doi:10.1038/s41523-016-0001-7 · Cited by 45
Malignant subclone drives metastasis of genetically and phenotypically heterogenous cell clusters through fibrotic niche generation
Kok, S. Y., Oshima, H., Takahashi, K., Nakayama, M., Murakami, K., Ueda, H. R., Miyazono, K., & Oshima, M. (2021) · Nature Communications · doi:10.1038/s41467-021-21160-0 · Cited by 43
The TP53 tumor suppressor gene: From molecular biology to clinical investigations
Baliakas, P., & Soussi, T. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20106 · Cited by 48
Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53
Zhao, Y., Zhang, C., Yue, X., Li, X., Liu, X. J., Yu, H., Белый, В. А., Yang, Q., Feng, Z., & Hu, W. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.33 · Cited by 42
Human-correlated genetic models identify precision therapy for liver cancer
Müller, M., May, S., Hall, H., Kendall, T. J., McGarry, L., Blukacz, L., Nuciforo, S., Γεωργακοπούλου, Α., Jamieson, T., Phinichkusolchit, N., et al. (2025) · Nature · doi:10.1038/s41586-025-08585-z · Cited by 40
Loss of P53 facilitates invasion and metastasis of prostate cancer cells
Wang, Y., Zhang, Y., Kong, C., Zhang, Z., & Zhu, Y. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1789-1 · Cited by 41
The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele
Shetzer, Y., Kagan, S., Koifman, G., Sarig, R., Kogan-Sakin, I., Charni, M., Kaufman, T., Zapatka, M., Molchadsky, A., Rivlin, N., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.57 · Cited by 43
The Contrived Mutant p53 Oncogene – Beyond Loss of Functions
Sabapathy, K. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00276 · Cited by 45
Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors
Peacock, J. D., Pridgeon, M. G., Tovar, E. A., Essenburg, C. J., Bowman, M. J., Madaj, Z., Koeman, J. M., Boguslawski, E. A., Grit, J. L., Dodd, R. D., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3167 · Cited by 41
OncoLoop: A Network-Based Precision Cancer Medicine Framework
Vasciaveo, A., Arriaga, J. M., de Almeida, F. N., Zou, M., Douglass, E. F., Picech, F., Shibata, M., Rodríguez-Calero, A., de Brot, S., Mitrofanova, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0342 · Cited by 38
Control of Genomic Instability and Epithelial Tumor Development by the p53-Fbxw7/Cdc4 Pathway
Pérez‐Losada, J., Mao, J., & Balmain, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1294 · Cited by 39
Osteosarcomagenesis: Modeling Cancer Initiation in the Mouse
Jones, K. B. (2011) · Sarcoma · doi:10.1155/2011/694136 · Cited by 40
The role of TP53 gain-of-function mutation in multifocal glioblastoma
Olafson, L. R., Gunawardena, M. P., Nixdorf, S., McDonald, K. L., & Rapkins, R. W. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03318-5 · Cited by 40
PIK3CA and p53 Mutations Promote 4NQO-Initated Head and Neck Tumor Progression and Metastasis in Mice
García‐Carracedo, D., Cai, Y., Qiu, W., Saeki, K., Friedman, R. A., Lee, A. H., Li, Y., Goldberg, E. M., Στρατικόπουλος, Η., Parsons, R. E., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0549 · Cited by 42
p53 and Hereditary Cancer
Merino, D. M., & Malkin, D. M. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_1 · Cited by 39
Characterization of Functional Domains Necessary for Mutant p53 Gain of Function
Yan, W., & Chen, X. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.097253 · Cited by 40
p53 −/− synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia
Zhang, J., Kong, G., Rajagopalan, A., Lu, L., Song, J., Hussaini, M., Zhang, X., Ranheim, E. A., Liu, Y., Wang, J., et al. (2016) · Blood · doi:10.1182/blood-2016-06-719237 · Cited by 43
Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer
Shakya, R., Tarulli, G. A., Sheng, L., Lokman, N. A., Ricciardelli, C., Pishas, K. I., Selinger, C. I., Kohonen‐Corish, M. R. J., Cooper, W. A., Turner, A. G., et al. (2017) · Oncogene · doi:10.1038/onc.2017.66 · Cited by 42
Restoring p53 in cancer: the promises and the challenges
Lozano, G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz063 · Cited by 41
Canonical TGFβ signaling induces collective invasion in colorectal carcinogenesis through a Snail1- and Zeb1-independent partial EMT
Flum, M., Dicks, S., Teng, Y.-H., Schrempp, M., Nyström, A., Boerries, M., & Hecht, A. (2022) · Oncogene · doi:10.1038/s41388-022-02190-4 · Cited by 41
p53 control of bone remodeling
Liu, H., & Li, B. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22749 · Cited by 39
A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion
Grugan, K. D., Vega, M. E., Wong, G. S., Diehl, J. A., Bass, A. J., Wong, K., Nakagawa, H., & Rustgi, A. K. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.25406 · Cited by 39
Gambogic acid counteracts mutant p53 stability by inducing autophagy
Foggetti, G., Ottaggio, L., Russo, D., Monti, P., Degan, P., Fronza, G., & Menichini, P. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.11.023 · Cited by 40
Exploiting the p53 Pathway for the Diagnosis and Therapy of Human CancerPreprint
Lane, D. P. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.049 · Cited by 40
Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo
Xiong, S., Chachad, D., Zhang, Y., Gencel‐Augusto, J., Sirito, M., Pant, V., Yang, P., Sun, C., Chau, G. P., Qi, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3376 · Cited by 42
Chromosome instability and deregulated proliferation: an unavoidable duo
Coschi, C. H., & Dick, F. A. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0910-4 · Cited by 40
Functions of TAp63 and p53 in restraining the development of metastatic cancer
Tan, E. H., Morton, J. P., Timpson, P., Tucci, P., Melino, G., Flores, E. R., Sansom, O. J., Vousden, K. H., & Muller, P. A. J. (2013) · Oncogene · doi:10.1038/onc.2013.287 · Cited by 39
Restoration of DNA‐binding and growth‐suppressive activity of mutant forms of p53 via a PCAF‐mediated acetylation pathway
Perez, R. E., Knights, C. D., Sahu, G., Catania, J., Kolukula, V. K., Stoler, D. L., Graessmann, A., Ogryzko, V. V., Pishvaian, M. J., Albanese, C., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22285 · Cited by 40
Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers
Riccardo, F., Arigoni, M., Buson, G., Zago, E. D., Iezzi, M., Longo, D. L., Carrara, M., Fiore, A., Nuzzo, S., Bicciato, S., et al. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-s3-s1 · Cited by 39
Ras and TGF-β signaling enhance cancer progression by promoting the ΔNp63 transcriptional program
Vasilaki, E., Morikawa, M., Koinuma, D., Mizutani, A., Hirano, Y., Ehata, S., Sundqvist, A., Kawasaki, N., Cedervall, J., Olsson, A., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aag3232 · Cited by 39
MDM4 is a rational target for treating breast cancers with mutant p53
Miranda, P. J., Buckley, D., Raghu, D., Pang, J., Takano, E. A., Vijayakumaran, R., Teunisse, A. F. A. S., Posner, A., Procter, T., Herold, M. J., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4877 · Cited by 39
Potential therapeutic targets ofTP53gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer
Tanaka, T., Watanabe, M., & Yamashita, K. (2018) · Oncotarget · doi:10.18632/oncotarget.24611 · Cited by 46
The inflammatory microenvironment that promotes gastrointestinal cancer development and invasion
Echizen, K., Oshima, H., Nakayama, M., & Oshima, M. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.02.001 · Cited by 40
Epigenetic synthetic lethality approaches in cancer therapy
Yang, H., Cui, W., & Wang, L. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0734-x · Cited by 37
Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer
Gasparyan, M., Lo, M., Jiang, H., Lin, C.-C. A., & Sun, D. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010710 · Cited by 38
Dual inhibition of DNA-PK and DNA polymerase theta overcomes radiation resistance induced by p53 deficiency
Kumar, R. J., Chao, H. X., Simpson, D. A., Feng, W., Cho, M.-G., Roberts, V., Sullivan, A. R., Shah, S., Wozny, A., Fagan‐Solis, K. D., et al. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa038 · Cited by 38
p53 regulates cytoskeleton remodeling to suppress tumor progression
Araki, K., Ebata, T., Guo, A. K., Tobiume, K., Wolf, S. J., & Kawauchi, K. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1989-9 · Cited by 41
Triple-negative breast tumors are dependent on mutant p53 for growth and survival
Dibra, D., Moyer, S. M., El‐Naggar, A. K., Qi, Y., Su, X., & Lozano, G. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2308807120 · Cited by 39
Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer
Mahat, D. B., Kumra, H., Castro, S. A., Metcalf, E., Nguyen, K. B., Morisue, R., Ho, W. W., Chen, I. X., Sullivan, B., Yim, L., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.06.005 · Cited by 44
P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency
Shapira, I., Lee, A., Vora, R. K., & Budman, D. R. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.003 · Cited by 41
Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer
Fendrich, V., Sparn, M. B., Lauth, M., Knoop, R. F., Plaßmeier, L., Bartsch, D. K., & Waldmann, J. (2013) · Pancreatology · doi:10.1016/j.pan.2013.08.002 · Cited by 38
Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin
Fuchigami, H., Manabe, S., Yasunaga, M., & Matsumura, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-32601-0 · Cited by 33
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System
Nieto‐Sampedro, M., Valle‐Argos, B., Gómez‐Nicola, D., Fernández‐Mayoralas, A., & Nieto‐Díaz, M. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7685 · Cited by 39
Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium
Ray-Coquard, I. L., Braicu, E. I., Berger, R., Mahner, S., Sehouli, J., Pujade-Lauraine, É., Cassier, P. A., Moll, U. M., Ulmer, H., Leunen, K., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00832 · Cited by 40
Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis
Yallowitz, A. R., Li, D., Lobko, A., Mott, D., Nemajerová, A., & Marchenko, N. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0360 · Cited by 36
Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma
Schofield, H. K., Zeller, J., Espinoza, C. E., Halbrook, C. J., Vecchio, A. D., Magnuson, B., Fabo, T., Daylan, A. E. C., Kovalenko, I., Lee, H., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97422 · Cited by 38
Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance
Chiou, S., Dorsch, M., Kusch, E., Naranjo, S., Kozak, M. M., Koong, A. C., Winslow, M. M., & Grüner, B. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-32159-x · Cited by 37
Gain-of-Function Mutations in p53 in Cancer Invasiveness and Metastasis
Roszkowska, K. A., Giziński, S., Sady, M., Gajewski, Z., & Olszewski, M. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041334 · Cited by 37
Replication stress promotes cell elimination by extrusion
Dwivedi, V. K., Pardo-Pastor, C., Droste, R., Kong, J. N., Tucker, N., Denning, D. P., Rosenblatt, J., & Horvitz, H. R. (2021) · Nature · doi:10.1038/s41586-021-03526-y · Cited by 37
Post-translational Modifications of the p53 Protein and the Impact in Alzheimer’s Disease: A Review of the Literature
Clark, J., Kayed, R., Kayed, R., Abate, G., Kinnon, P., & Kinnon, P. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.835288 · Cited by 38
Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo
Wahl, G. M. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401911 · Cited by 37
Induced mitotic recombination of p53 in vivo
Wang, W., Warren, M. V., & Bradley, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607953104 · Cited by 37
The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations
Ma, F., Laster, K. V., & Dong, Z. (2022) · Nature Communications · doi:10.1038/s41467-022-33351-4 · Cited by 42
SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer
Li, H., Lan, L., Chen, H., Thin, M. Z., Hari, P. S., Nelson, J. K., Evans, I. M., Ruiz, E. J., Cheng, R., Tran, L., et al. (2025) · Nature · doi:10.1038/s41586-025-09574-y · Cited by 46
NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability
Croessmann, S., Wong, H. Y., Zabransky, D. J., Chu, D. T. W., Mendonca, J., Sharma, A. R., Mohseni, M., Rosen, D. M., Scharpf, R. B., Cidado, J. R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503683112 · Cited by 36
Ionizing radiation induces a dramatic persistence of p53 protein accumulation and DNA damage signaling in mutant p53 zebrafish
Guo, L., Liew, H. P., Camus, S., Goh, A. M., Chee, L., Lunny, D. P., Lane, E. B., & Lane, D. P. (2012) · Oncogene · doi:10.1038/onc.2012.409 · Cited by 37
Osteosarcoma Models: From Cell Lines to Zebrafish
Mohseny, A. B., Hogendoorn, P. C. W., & Cleton-Jansen, A. (2012) · Sarcoma · doi:10.1155/2012/417271 · Cited by 36
Modeling human osteosarcoma in the mouse: From bedside to bench
Janeway, K. A., & Walkley, C. R. (2010) · Bone · doi:10.1016/j.bone.2010.07.028 · Cited by 36
Mutant p53 in concert with an IL27 Receptor α deficiency causes spontaneous liver inflammation, fibrosis, and steatosis
Dibra, D., Xia, X., Mitra, A., Cutrera, J., Lozano, G., & Li, S.-L. (2016) · Hepatology · doi:10.1002/hep.28379 · Cited by 30
The role of tumor suppressor p53 in metabolism and energy regulation, and its implication in cancer and lifestyle-related diseases
Hashimoto, N., Nagano, H., & Tanaka, T. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0565 · Cited by 37
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
Hancock, B. A., Chen, Y.-H., Solzak, J. P., Ahmad, M. N., Wedge, D. C., Brinza, D., Scafe, C., Veitch, J. M., Gottimukkala, R., Short, W., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1171-7 · Cited by 37
Modeling germline mutations in pineoblastoma uncovers lysosome disruption-based therapy
Chung, P. E. D., Gendoo, D. M. A., Ghanbari-Azarnier, R., Liu, J. C., Jiang, Z., Tsui, J., Wang, D., Xiao, X., Li, B. K., Dubuc, A. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15585-2 · Cited by 38
Impact of cholesterol-pathways on breast cancer development, a metabolic landscape
González-Ortiz, A., Galindo‐Hernández, O., Acevedo, G. N. H., Hurtado-Ureta, G., & García‐González, V. (2021) · Journal of Cancer · doi:10.7150/jca.54637 · Cited by 40
Mutant p53 elicits context-dependent pro-tumorigenic phenotypes
McCann, J. J., Vasilevskaya, I. A., McNair, C. M., Gallagher, P., Neupane, N. P., de Leeuw, R., Shafi, A. A., Dylgjeri, E., Mandigo, A. C., Schiewer, M. J., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01903-5 · Cited by 40
BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation
Li, B., An, W., Wang, H., Baslan, T., Mowla, S., Krishnan, A., Xiao, W., Koche, R. P., Liu, Y., Cai, S. F., et al. (2022) · Blood · doi:10.1182/blood.2021014465 · Cited by 38

Authors: Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T.
Affiliations: Massachusetts Institute of Technology (US)
Abramson Cancer Center (US)
Tufts University (US)
Howard Hughes Medical Institute (US)
Corresponding author: Jacks, Tyler
ORCID: Olive, Kenneth P.
Tuveson, David A.
Ruhe, Zachary C.
Willis, Nicholas A.
Bronson, Roderick T.
Jacks, Tyler
Venue: Cell
Publisher: Elsevier BV
Published: 2004-12
Volume: 119
Issue: 6
Pages: 847-860
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2004.11.004
OpenAlex: W2079852484
Cited by: 1,308
References: 64
Citations by year: 2026: 26 · 2025: 49 · 2024: 52 · 2023: 87 · 2022: 52 · 2021: 64 · 2020: 67 · 2019: 69 · 2018: 74 · 2017: 69 · 2016: 78 · 2015: 75 · 2014: 97 · 2013: 64 · 2012: 51
FWCI: 21.50
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3150 d)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: p53, Li-Fraumeni syndrome, gain-of-function mutations, missense mutations, dominant-negative p53, tumor suppressor, mouse model, endothelial tumors, carcinoma, oncogenicity
MeSH terms: Alleles, Animals, Carcinoma, Mice, Transgenic, Mutation, Neoplasms, T-Lymphocytes, Gene Expression Regulation, Neoplastic, Genes, p53, Li-Fraumeni Syndrome, Apoptosis, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks